Johnson & Johnson on Track for Lowest Close Since November 2020 — Data Talk
Johnson & Johnson (JNJ) is currently at $145.12, down $2.47 or 1.67%
--Would be lowest close since Nov. 30, 2020, when it closed at $144.68
--On pace for largest percent decrease since April 3, 2024, when it fell 2.2%
--Currently down four of the past five days
--Down 8.26% month-to-date
--Down 7.41% year-to-date
--Down 21.98% from its all-time closing high of $186.01 on April 25, 2022
--Down 9.87% from 52 weeks ago (April 18, 2023), when it closed at $161.01
--Down 16.83% from its 52-week closing high of $174.48 on July 28, 2023
--Would be a new 52-week closing low
--Traded as low as $143.67; lowest intraday level since Nov. 30, 2020, when it hit $143.06
--Down 2.66% at today's intraday low; largest intraday percent decrease since Jan. 23, 2024, when it fell as much as 3.42%
--Second worst performer in the DJIA today
--Subtracted 16.23 points from the DJIA so far today
All data as of 10:55:07 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 16, 2024 11:12 ET (15:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?